Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis

Critical Care

Volumn 7, Issue 2, 2003, Pages 155-163

  Bernard, Gordon R ^a   Macias, William L ^b   Joyce, David E ^b   Williams, Mark D ^b   Bailey, Joan ^b   Vincent, Jean Louis ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c ERASME HOSPITAL   (Belgium)

Author keywords

Activated protein C; Drotrecogin alfa (activated); Mortality; Safety; Severe sepsis

Indexed keywords

DROTRECOGIN; PLACEBO;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DATA ANALYSIS; DATA BASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; HUMAN; MENINGITIS; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEPSIS; THROMBOCYTOPENIA;

ADULT; ANTI-INFECTIVE AGENTS; CONSUMER PRODUCT SAFETY; HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS;

EID: 0037389471     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc2167     Document Type: Review

References (12)

1. Esmon CT: The protein C anticoagulant pathway. Arterioscler Thromb 1992, 12:135-145.
2. Walker FJ, Sexton PW, Esmon CT: The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta 1979, 571:333-342.
3. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS: Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V [abstract]. Blood 1984, 63:486-489.
4. Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ: The Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group, Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
5. Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE, Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan BS, Helterbrand JD, on behalf of the rhAPC Sepsis Study Group: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001, 29:2051-2059.
6. Eli Lilly and Company: Xigris™ [package insert]. Indianapolis, IN: Eli Lilly and Company; 2001.
7. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
8. Vincent J-L, Angus DC, Artigas A, Kalil A, Basson B, Jamal HH, Johnson G III, Bernard GR, for the Recombinant Human Activated Protein C Worldwide Evaluation of Severe Sepsis (PROWESS) Study Group: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003:in press.
9. Abraham W, Reinhart K, Svoboda P, Selbert A, Olthoff D, Nogare AD, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA: Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, does escalation study. Crit Care Med 2001, 29:2081-2089.
10. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM, KyberSept Trial Study Group: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878.
11. Macias WL, Dhainaut J-F, Yan SB, Helterbrand JD, Seger M, Johnson G III, Small DS: Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 2002, 72:391-402.
12. Oppenheim-Eden A, Glantz L, Eidelman LA, Sprung CL: Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors. Intensive Care Med 1999, 25:63-67.